Rutherfold, NJ - According to Emily Badger of NJBiz, "Cancer Genetics Inc., a provider of DNA-based cancer diagnostics, announced Monday that it has agreed to acquire the assets and operations of Los Angeles-based Response Genetics Inc. Rutherford-based Cancer Genetics said in a news release that as part of the transaction, Response Genetics, a solid tumor molecular diagnostics, has filed chapter 11 bankruptcy in the Delaware Bankruptcy Court."
New Brunswick, NJ – One in six men will be diagnosed with prostate cancer and it is the most frequently diagnosed cancer in men other than skin cancer, according to the American Cancer Society. That is why Rutgers Cancer Institute of New Jersey and its flagship hospital Robert Wood Johnson University Hospital (RWJ) are joining forces to offer a free prostate cancer education and screening event, to provide men and their families with a better understanding of the disease. Registration for the event, which has tested thousands of men over the past 17 years, is now open and will be offered to men across the state on September 15, 16 and 17 in recognition of National Prostate Cancer Awareness Month.
New Brunswick, N.J. – Several physicians at Rutgers Cancer Institute of New Jersey have been named as a ‘Top Cancer Doctor’ by Newsweek magazine. Newsweek just released the list of the nation’s top physicians for cancer care in conjunction with Castle Connolly Medical Ltd., which publishes America’s Top Doctors. Based on peer nominations, attributes such as board certification, clinical skills, training, years in practice, administrative posts, achievements and other criteria are reviewed and assessed by a physician-led research team assembled by Castle Connolly. According to Castle Connolly, nearly 100,000 nominations are received each year for the honor. In New Jersey alone, 40 Top Cancer Doctors were named to the national list – nine are from the Cancer Institute of New Jersey.
Hackensack, NJ – According to New Jersey Business Magazine, “Georgetown Lombardi Comprehensive Cancer Center, part of Georgetown University Medical Center in Washington, and John Theurer Cancer Center, part of Hackensack University Medical Center in Hackensack, have announced that they have developed a joint cancer research agenda as part of a multi-year plan to form a National Cancer Institute (NCI) recognized cancer consortium. This recognition would support the scientific excellence of the two centers along with their capability to integrate multi-disciplinary, collaborative research approaches to focus on all the aspects of cancer.
Basking Ridge, NJ - According to Eric Strauss of NJBiz, "Memorial Sloan Kettering Cancer Center has plans to develop a $140 million outpatient cancer center in Montvale, and now it looks like it has the property to do it. On Thursday, real estate investment trust Chambers Street Properties announced it has sold a 142,500-square-foot office building in the borough to an affiliate of the cancer center for $37 million."
New Brunswick, N.J. – David Mulvihill, MD, chief resident of radiation oncology at Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School and Robert Wood Johnson University Hospital, has been selected to receive a Young Investigator Award from the Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO). Dr. Mulvihill will be recognized at the ASCO Annual Meeting that begins later this week in Chicago.
Rutherford, NJ - Cancer Genetics, Inc. announced that it was selected by Japanese regenerative medicine company, ReproCELL, Inc., to provide next-generation sequencing (NGS) based services and molecular information to enhance ReproCELL’s translational medicine initiatives. Under the terms of the agreement, CGI will perform NGS using its recently launched Focus::Hotspot™ panel.
Camden, NJ - According to Beth Fitzgerald, "The new Janet Knowles Breast Cancer Center opened this week at the MD Anderson Cancer Center at Cooper in Camden. Cooper said in the first year since MD Anderson Cancer Center at Cooper opened, the cancer program has experienced more than 26 percent growth in new patients seeking specialized cancer services. This led to the decision to use existing shell space within the MD Anderson Cancer Center at Cooper to create the new breast cancer center."
Trenton, NJ - Cigna and Regional Cancer Care Associates LLC (RCCA) have started a program that aims to improve care for people receiving chemotherapy to treat any type of cancer. The program is an extension of Cigna Collaborative Care, a value-based initiative that uses incentives to engage health care professionals and help drive improved health, affordability and patient experience. Cigna Collaborative Care initially focused on large primary care physician groups but was expanded to include hospitals, small primary care practices and specialists, including oncologists.
New Brunswick, NJ - The Big Ten Cancer Research Consortium interviewed Robert S. DiPaola, MD, director of Rutgers Cancer Institute of New Jersey. The following was his question and answer on Big Ten Cancer Research Consortium website.
Montvale, NJ – According to Beth Fitzgerald of NJBiz, “Memorial Sloan Kettering Cancer Center said it will develop a third New Jersey outpatient cancer center, a $140 million Montvale facility that it hopes to open in April 2017. Sloan Kettering operates six outpatient cancer centers outside New York City, including a Basking Ridge center that opened in 2006 and a Middletown facility set to open next year. About 80 percent of cancer care is now delivered in outpatient facilities, and Sloan Kettering is part of a major expansion of outpatient cancer care underway throughout the state.”
New Brunswick, NJ - Michigan has autos. The Midwest has agribusiness. Texas has oil and gas. California’s Silicon Valley has electronics. And New Jersey has the life sciences industry. When Johnson & Johnson opened its doors in 1886 in a former New Brunswick wallpaper factory, it was the launch of what is today one of the largest healthcare companies in the world. It also was the genesis of what is currently the greatest concentration of life sciences companies not only in the United States but in the world — and New Jersey’s premier industry.
Princeton, NJ - Mark Esposito stood before a panel of judges at the Keller Center's 10th annual Innovation Forum on Feb. 25 and made a bold statement — a leap forward in cancer treatment is close at hand. "The problem is we're treating the wrong disease," said Esposito, a Princeton University graduate student in molecular biology. Esposito took the top prize at the Innovation Forum, an event for University researchers to present potentially marketable discoveries, with his pitch for a method to stop the spread of cancer, called metastasis.
Princeton, NJ - Five innovative projects have been awarded support through Princeton University's Dean for Research innovation funds. According to Catherine Zandonella of the Office of the Dean for Research, this fund is in its second year, the program enables faculty members to pursue bold new ideas. "Three projects in the natural sciences will receive $200,000 each over two years and will explore original, early-stage ideas that could serve as the basis of a larger research initiative. In addition, two collaborations with biomedical engineering and neuroscience companies will receive $100,000 each for the first year; Princeton will match each company's contribution of up to $75,000 in the second year."
New Brunswick, NJ - According to Howard Kaufman of the Rutgers Cancer Institute of New Jersey, the state has a promising future in precision immunology and personalized medicine. The associate director for clinical science and chief surgical officer at the Cancer Institute also spells out what needs to be accomplished in his Question and Answer.
For the full article: http://www.mycentraljersey.com/story/life/wellness/2015/02/02/health-precision-immunology/22597811/
Do not miss a single innovative moment and sign up for our newsletter!